UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 683

Sortiert nach

2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults

Canadian journal of cardiology, 2021-08, Vol.37 (8), p.1129-1150

2021

Volltextzugriff (PDF)

Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study

The lancet. Diabetes & endocrinology, 2015-02, Vol.3 (2), p.114-122

2015

Volltextzugriff (PDF)

The Challenges and Benefits of Cardiovascular Risk Assessment in Clinical Practice

Canadian journal of cardiology, 2011-07, Vol.27 (4), p.481-487

2011

Volltextzugriff (PDF)

The Measurable Benefits of a Workplace Wellness Program in Canada: Results After One Year

Journal of occupational and environmental medicine, 2018-03, Vol.60 (3), p.211-216

2018

Volltextzugriff (PDF)

Gambling With Cardiovascular Disease Risk Models: How to Choose and How to Use

Canadian journal of cardiology, 2021-05, Vol.37 (5), p.786-789

2021

Volltextzugriff (PDF)

The Sustainability of a Workplace Wellness Program That Incorporates Gamification Principles: Participant Engagement and Health Benefits After 2 Years

American journal of health promotion, 2019-07, Vol.33 (6), p.850-858

2019

Volltextzugriff (PDF)

Cardiovascular Risk Assessment and Follow-Up of Women After Hypertensive Disorders of Pregnancy:A Prospective Cohort Study

Journal of obstetrics and gynaecology Canada, 2019-08, Vol.41 (8), p.1157-1167.e1

2019

Volltextzugriff (PDF)

Outpatient Therapies for COVID-19: How Do We Choose?

Open forum infectious diseases, 2022-03, Vol.9 (3), p.ofac008-ofac008

2022

Volltextzugriff (PDF)

How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease?

Diabetes care, 2001-01, Vol.24 (1), p.45-50

2001

Volltextzugriff (PDF)

The preventing recurrent vascular events and neurological worsening through intensive organized case-management (PREVENTION) trial protocol [clinicaltrials.gov identifier: NCT00931788]

Implementation science : IS, 2010-04, Vol.5 (1), p.27-27, Article 27

2010

Volltextzugriff (PDF)

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels

Archives of internal medicine (1960), 2009-10, Vol.169 (19), p.1775

2009

Volltextzugriff (PDF)

Preventing cardiovascular disease among Canadians: What are the potential benefits of treating hypertension or dyslipidemia?

Canadian journal of cardiology, 2007-05, Vol.23 (6), p.467-473

2007

Volltextzugriff (PDF)

The association between sleep disturbance, depressive symptoms, and health-related quality of life among cardiac rehabilitation participants

Journal of cardiopulmonary rehabilitation and prevention, 2014-05, Vol.34 (3), p.188

2014

Volltextzugriff (PDF)

Determining the cost-effectiveness of preventing cardiovascular disease: Are estimates calculated over the duration of a clinical trial adequate?

Canadian journal of cardiology, 2008-04, Vol.24 (4), p.261-266

2008

Volltextzugriff (PDF)

Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis

CMAJ open, 2018-04, Vol.6 (2), p.E162-E167

2018

Volltextzugriff (PDF)

Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy

The American journal of cardiology, 2005-03, Vol.95 (5), p.586-591

2005

Volltextzugriff (PDF)

Discussing Coronary Risk with Patients to Improve Blood Pressure Treatment: Secondary Results from the CHECK-UP Study

Journal of general internal medicine : JGIM, 2009-01, Vol.24 (1), p.33-39

2009

Volltextzugriff (PDF)

Perspectives on Ethical Leadership

1, 2014

Volltextzugriff (PDF)

Treating Osteoarthritis With Cyclooxygenase-2–Specific Inhibitors: What Are the Benefits of Avoiding Blood Pressure Destabilization?

Hypertension (Dallas, Tex. 1979), 2005-01, Vol.45 (1), p.92-97

2005

Volltextzugriff (PDF)

Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?

JAMA : the journal of the American Medical Association, 1995-09, Vol.274 (10), p.801

1995

Volltextzugriff (PDF)

Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: Who should be treated?

Circulation (New York, N.Y.), 2000-08, Vol.102 (7), p.722-727

2000

Volltextzugriff (PDF)

Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus

Arthritis and rheumatism, 2001-10, Vol.44 (10), p.2331-2337

2001

Volltextzugriff (PDF)

The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease

Archives of internal medicine (1960), 2006-01, Vol.166 (2), p.213

2006

Volltextzugriff (PDF)

Improving the Prediction of Cardiovascular Risk: Interaction between LDL and HDL Cholesterol

Epidemiology (Cambridge, Mass.), 2003-05, Vol.14 (3), p.315-320

2003

Volltextzugriff (PDF)

PROVE-IT proves that lower is better: A contrary view

Canadian journal of cardiology, 2006-02, Vol.22 (Suppl B), p.95B-96B

Grover, Steven A.

2006

Volltextzugriff (PDF)

1 – 25 von 683

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(597)
Mit Volltextzugriff
(589)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(366)
Life Sciences & Biomedicine
(346)
Humans
(242)
Male
(164)
Female
(158)
Biological And Medical Sciences
(131)
Middle Aged
(114)
Medical Sciences
(107)
Adult
(103)
Cardiovascular System & Cardiology
(100)
Animals
(95)
Aged
(94)
Cardiac & Cardiovascular Systems
(70)
Risk Factors
(60)
Social Sciences
(52)
Hematology
(51)
General & Internal Medicine
(46)
Peripheral Vascular Disease
(43)
Medicine, General & Internal
(42)
Management
(36)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults

Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study

The Challenges and Benefits of Cardiovascular Risk Assessment in Clinical Practice

The Measurable Benefits of a Workplace Wellness Program in Canada: Results After One Year

Gambling With Cardiovascular Disease Risk Models: How to Choose and How to Use

The Sustainability of a Workplace Wellness Program That Incorporates Gamification Principles: Participant Engagement and Health Benefits After 2 Years

Cardiovascular Risk Assessment and Follow-Up of Women After Hypertensive Disorders of Pregnancy:A Prospective Cohort Study

Outpatient Therapies for COVID-19: How Do We Choose?

How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease?

The preventing recurrent vascular events and neurological worsening through intensive organized case-management (PREVENTION) trial protocol [clinicaltrials.gov identifier: NCT00931788]

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels

Preventing cardiovascular disease among Canadians: What are the potential benefits of treating hypertension or dyslipidemia?

The association between sleep disturbance, depressive symptoms, and health-related quality of life among cardiac rehabilitation participants

Determining the cost-effectiveness of preventing cardiovascular disease: Are estimates calculated over the duration of a clinical trial adequate?

Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis

Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy

Discussing Coronary Risk with Patients to Improve Blood Pressure Treatment: Secondary Results from the CHECK-UP Study

Perspectives on Ethical Leadership

Treating Osteoarthritis With Cyclooxygenase-2–Specific Inhibitors: What Are the Benefits of Avoiding Blood Pressure Destabilization?

Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?

Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: Who should be treated?

Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus

The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease

Improving the Prediction of Cardiovascular Risk: Interaction between LDL and HDL Cholesterol

PROVE-IT proves that lower is better: A contrary view

Suchergebnisse filtern